Paper Details

  1. Home
  2. Paper Details

A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.

Author: BellK, CooperT B, DevanandD P, MarderK, MayeuxR, MichaelsK S, PeltonG H, SackeimH A, SullivanM A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Haloperidol in a dose of 2-3 mg/day was effective in treating psychosis and disruptive behaviors in patients with Alzheimer's disease, with a higher response rate than low-dose haloperidol or placebo. However, a subgroup of patients experienced moderate to severe extrapyramidal signs.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease. METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A)...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1176/ajp.155.11.1512

データ提供：米国国立医学図書館（NLM）

Haloperidol for Psychosis and Disruptive Behaviors in Alzheimer's Disease: A Dose-Comparison Trial

Alzheimer's disease, a formidable desert of cognitive decline, often presents with psychosis and disruptive behaviors. This research investigates the efficacy and side effects of two doses of haloperidol, an antipsychotic medication, in treating these challenging symptoms. The study, conducted in a double-blind, placebo-controlled manner, compared the effects of a standard dose and a low dose of haloperidol in patients with Alzheimer's disease. The results showed that the standard dose of haloperidol was superior to both the low dose and placebo in reducing psychosis and agitation. While the standard dose was associated with a higher risk of extrapyramidal signs, a starting dose of 1 mg/day with gradual titration is recommended to minimize these side effects.

Standard Dose Haloperidol: A Promising Treatment Option

The study's findings indicate that a standard dose of haloperidol (2-3 mg/day) was more effective than a low dose or placebo in treating psychosis and disruptive behaviors in Alzheimer's disease. This suggests that a standard dose of haloperidol may be a valuable treatment option for these challenging symptoms, helping patients navigate the often-difficult landscape of Alzheimer's disease.

Navigating Alzheimer's: Balancing Efficacy and Safety

While the standard dose of haloperidol showed promise in treating psychosis and disruptive behaviors in Alzheimer's disease, the study also highlighted the potential for extrapyramidal signs, a common side effect of antipsychotics. This finding emphasizes the need for careful monitoring and individualized dosing strategies to maximize therapeutic benefit while minimizing potential side effects. It's like navigating a desert with a compass and a map, carefully balancing our path to ensure both safety and progress.

Dr. Camel's Conclusion

Treating psychosis and disruptive behaviors in Alzheimer's disease is like finding a source of water in a vast and unforgiving desert. This study offers valuable insights into the potential of haloperidol as a treatment option, but reminds us that careful consideration of dosage and potential side effects is crucial. As we continue to seek better therapies for Alzheimer's disease, we must strive for both effectiveness and safety, ensuring that our journey through this challenging landscape is as smooth and comfortable as possible.

Date :
  1. Date Completed 1998-11-23
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

9812111

DOI: Digital Object Identifier

10.1176/ajp.155.11.1512

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.